Next Article in Journal
Reconstructive Arthrodesis for Advanced Ankle and Subtalar Joint Destruction in Neuropathic and Infected Feet
Previous Article in Journal
Changes to the Intercondylar Ligaments of the Knee in Different Stages of Osteoarthritis—A Retrospective Cross-Sectional Study
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

Autoimmune Hepatitis and Drug-Induced Liver Injury in Japan

1
Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan
2
Department of Gastroenterology, Kobe Asahi Hospital, Kobe 653-8501, Hyogo, Japan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2025, 14(13), 4514; https://doi.org/10.3390/jcm14134514 (registering DOI)
Submission received: 29 April 2025 / Revised: 21 June 2025 / Accepted: 24 June 2025 / Published: 25 June 2025

Abstract

Autoimmune hepatitis (AIH) is the most common liver disease caused by autoimmunity. In Japan, the number of patients with AIH has been increasing in recent years. AIH develops as a result of the loss of immune tolerance to autoantigens in the liver. Drug-induced liver injury (DILI) is an extremely important cause of liver injury in clinical practice and should always be kept in mind in the differential diagnosis. Recently, DILI caused by immune checkpoint inhibitors has been attracting attention. For the diagnosis of DILI, it is important to carefully exclude other possible causes of liver injury and obtain a detailed history of medications and the timing of their use. On the other hand, drug-induced AIH, like hepatitis, also exists and is clinically important because it is often difficult to differentiate from idiopathic AIH. A solid understanding of the pathogenesis of both AIH and DILI is essential for clinicians. This article provides an overview of AIH and DILI in Japan, including the latest findings.
Keywords: autoimmune hepatitis; drug-induced liver injury; pathogenesis; diagnosis; treatment; Japan autoimmune hepatitis; drug-induced liver injury; pathogenesis; diagnosis; treatment; Japan

Share and Cite

MDPI and ACS Style

Nishikawa, H.; Kim, S.K.; Asai, A. Autoimmune Hepatitis and Drug-Induced Liver Injury in Japan. J. Clin. Med. 2025, 14, 4514. https://doi.org/10.3390/jcm14134514

AMA Style

Nishikawa H, Kim SK, Asai A. Autoimmune Hepatitis and Drug-Induced Liver Injury in Japan. Journal of Clinical Medicine. 2025; 14(13):4514. https://doi.org/10.3390/jcm14134514

Chicago/Turabian Style

Nishikawa, Hiroki, Soo Ki Kim, and Akira Asai. 2025. "Autoimmune Hepatitis and Drug-Induced Liver Injury in Japan" Journal of Clinical Medicine 14, no. 13: 4514. https://doi.org/10.3390/jcm14134514

APA Style

Nishikawa, H., Kim, S. K., & Asai, A. (2025). Autoimmune Hepatitis and Drug-Induced Liver Injury in Japan. Journal of Clinical Medicine, 14(13), 4514. https://doi.org/10.3390/jcm14134514

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop